Advertisement

Gaining knowledge for the choice and use of systemic therapies in the treatment of hepatocellular carcinoma also requires real life and investigators conducted observational studies

Published:September 17, 2022DOI:https://doi.org/10.1016/j.dld.2022.08.032
      In this issue of Digestive and Liver Disease, ITA.LI.CA. a large, well-known, efficient and productive Italian cooperative group devoted to the study of liver cancer analyzed the theoretical eligibility for the combination of atezolizumab plus bevacizumab among their patients with advanced HCC who received at least one dose of systemic therapy with a tyrosin kinase inhibitor (TKI) [
      • Stefanini B
      • Bucci L
      • Santi V
      • Magalotti D
      • Trevisani F
      for the Italian Liver Cancer (ITA.LI.CA) group. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors.
      ]. Eligibility was assessed according to the criteria adopted for the IMBRAVE 150 phase 3 registration trial [
      • Finn RS
      • Qin S
      • Ikeda M
      • et al.
      Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
      ] and was found to reach hardly 30% of all patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stefanini B
        • Bucci L
        • Santi V
        • Magalotti D
        • Trevisani F
        for the Italian Liver Cancer (ITA.LI.CA) group. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors.
        Dig Liv Dis. 2022; 54: 1563-1572https://doi.org/10.1016/j.dld.2022.07.003
        • Finn RS
        • Qin S
        • Ikeda M
        • et al.
        Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
        N Engl J Med. 2020; 382: 1894-1905https://doi.org/10.1056/NEJMoa1915745
        • Marrero JA
        • Kudo M
        • Venook AP
        • et al.
        Observational registry of sorafenib use in clinical practice across child-pugh subgroups: the GIDEON study.
        J Hepatol. 2016; 65: 1140-1147https://doi.org/10.1016/j.jhep.2016.07.020
        • Peck-Radosavljevic M
        • Goyal L
        • Strasser S
        • et al.
        A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of Lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).
        J Clin Oncol. 2022; 40 (-TPS485): TPS485
        • Iavarone M
        • Cabibbo G
        • Piscaglia F
        • et al.
        Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
        Hepatology. 2011; 54: 2055-2063https://doi.org/10.1002/hep.24644
        • Burgio V
        • Iavarone M
        • Di Costanzo GG
        • et al.
        Real-life clinical data of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma in Italy.
        Cancer Manag Res. 2021; 24: 9379-9389https://doi.org/10.2147/CMAR.S330195
        • D'Alessio A
        • Fulgenzi CAM
        • Nishida N
        • et al.
        Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.
        Hepatology. 2022; (Published online March 21)https://doi.org/10.1002/hep.32468
        • Llovet JM
        • Ricci S
        • Mazzaferro V
        • et al.
        Sorafenib in advanced hepatocellular carcinoma.
        N Engl J Med. 2008; 359: 378-390https://doi.org/10.1056/NEJMoa0708857
        • Kudo M
        • Finn RS
        • Qin S
        • et al.
        Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
        Lancet. 2018; 24 (10126): 1163-1173
        • Abou-Alfa Ghassan K
        • Lau G
        • Kudo M
        • et al.
        Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
        NEJM Evid. 2022; 1https://doi.org/10.1056/EVIDoa2100070
        • McNamara MG
        • Slagter AE
        • Nuttall C
        • et al.
        Sorafenib as first-line therapy in patients with advanced child-pugh B hepatocellular carcinoma-a meta-analysis.
        Eur J Cancer. 2018; 105: 1-9https://doi.org/10.1016/j.ejca.2018.09.031
        • Raoul JL
        • Bruix J
        • Greten TF
        • et al.
        Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
        J Hepatol. 2012; 56: 1080-1088https://doi.org/10.1016/j.jhep.2011.12.009
        • Giannini EG
        • Pieri G
        • Labanca S
        • et al.
        Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma.
        Dig Liver Dis. 2022; 27 (S1590-8658(22)00205-5)https://doi.org/10.1016/j.dld.2022.03.002
        • Cabibbo G
        • Aghemo A
        • Lai Q
        • Masarone M
        • Montagnese S
        • Ponziani FR
        • Italian Association for the Study of the Liver (AISF)
        Optimising systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.
        Dig Liver Dis. 2022; 54: 452-460https://doi.org/10.1016/j.dld.2022.01.122
        • D'Avola D
        • Granito A
        • Torre-Aláez M
        • Piscaglia F
        The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma.
        J Hepatol. 2022; 76: 1185-1198https://doi.org/10.1016/j.jhep.2021.11.013

      Linked Article